Loading clinical trials...

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients | Clinical Trials | Clareo Health

COMPLETEDNA

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

A FIH Feasibility Study to Evaluate the Safety of Transient Disruption of Blood-brain Barrier in Recurrent Glioblastoma Multiforme (GBM) Patients Using NaviFUS System

NCT03626896•NaviFUS Corporation

View on ClinicalTrials.gov

Summary

This study is to evaluate the safety and find the tolerated ultrasound dose of transient opening of the blood-brain barrier (BBB) by using the NaviFUS System in recurrent GBM patients.

Detailed Description

This is a feasibility, open-label, single-arm, and dose escalation study. Eligible patients will be enrolled through the process of informed consent. Patients will be assigned into different dose groups generated from the NaviFUS System to transiently open the BBB in patients with recurrent GBM who will undergo surgery within 2 weeks. The focused ultrasound (FUS) dose is selected based on the results of pre-clinical Good Laboratory Practice (GLP) safety studies as well as other non-GLP primate studies. This study will evaluate the safety and the tolerated ultrasound dose of temporary disruption of the BBB in patients with recurrent GBM. To find the tolerated ultrasound dose, the data and safety monitoring board (DSMB) will review the study data and provide the recommendations regarding continuation, termination, or other modifications of the study based on evaluation of observed adverse effects of the intervention. The extent and magnitude of BBB opening will be evaluated using of dynamic contrast-enhanced MRI (DCE-MRI).

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients diagnosed with recurrent GBM and will undergo surgery
•Able to give written informed consent for the participation in the trial
•Adult male/female patients \> 20 years of age
•Patients if already on radiotherapy, a gap of 7 days shall be maintained between the last day of radiotherapy and the day of screening
•Patients if already on the steroids treatment, then should be on a stable dose of steroids for at least 7 days prior to screening
•Body mass index (BMI) ≥17 kg / m2
•Patients with life expectancy ≥ 3 months
•Able to comply with study requirements in the opinion of the investigator
•Adequate hepatic, renal, coagulation, and hematopoietic function
•* Hemoglobin ≥ 10 g/dL
+10 more criteria

Exclusion Criteria

•Patients at screening visit have arteriovenous malformation (AVM) or cerebral aneurysm
•Use of any recreational drugs or history of drug addiction
•Pregnant or breast-feeding women
•The receipt of an investigational drug, or participation in a drug research study within a period of one month prior to the first FUS exposure
•Known sensitivity/allergy to MRI contrast agents, CT contrast agents, SonoVue®, or any of its components
•Any other condition that, in the investigator's judgment, might increase the risk to the patients or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study
•Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints
•Patients who have hemorrhage or cyst within the ROI
•Severe hypertension at screening (diastolic blood pressure \> 100 mmHg on medication)
•Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week prior to study treatment or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month prior to study treatment

Locations (1)

Linkou Chang Gung Memorial Hospital

Taoyuan, Taiwan

Key Dates

Start Date

August 17, 2018

Primary Completion Date

May 20, 2019

Completion Date

June 19, 2019

Last Updated

June 21, 2019

Enrollment

ACTUAL participants

Conditions

Glioblastoma MultiformeBrain TumorGlioblastomaGliomaNeoplasmsNeoplasms, Nerve Tissue

Interventions

NaviFUS System

DEVICE

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 21, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Inclusion Criteria

Exclusion Criteria

Targeted Pediatric High-Grade Glioma Therapy

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

The Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery (IPSIMANON)

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma